bluebird bio Inc. (BLUE) announced Thursday morning that interim data from its ongoing Phase 1 clinical study of bb2121, will be presented today at the 28th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium in Munich, Germany.
from RTT - Hot Stocks http://ift.tt/2gCTNHU
via IFTTT
No comments:
Post a Comment